Time filter

Source Type

Gliwice, Poland

Huszno J.,Klinika Onkologii Klinicznej i Doswiadczalnej | Nowara E.,Klinika Onkologii Klinicznej i Doswiadczalnej | Suwinski R.,II Klinika Radioterapii

Pharmacogenetics is a rapidly developing area of pharmacology aimed at therapeutic individualization i.e. the identification of patients who are most likely to benefit from a given treatment with minimal side effects. Pharmacogenetics investigates individual variability which results from the presence of genetic polymorphisms, mutations and varied gene expression. In this study we concentrated on the influence of polymorphisms on the function of proteins which participate in drug transport and metabolism and on the mechanisms of DNA repair. These processes influence drug activity, the efficacy of therapy therapeutic and the possible side effects. The paper presents the pharmacogenetics of drugs commonly used in oncology, including the mechanisms of drug transport and metabolism with special interest placed on the polymorphisms of genes encoding phase I and II proteins for enzymes and genes encoding transporting proteins. Source

Huszno J.,Klinika Onkologii Klinicznej i Doswiadczalnej | Nowara E.,Klinika Onkologii Klinicznej i Doswiadczalnej | Suwinski R.,II Klinika Radioterapii
Onkologia Polska

Tyrosine kinase inhibitors (TKIs) therapy (tyrosine kinase inhibitors of the EGFR, kinase inhibitors of BCR-ABL, VEGFR and PDGFR kinases inhibitors) selectively inhibit transmission pathway of signals essential for proliferation, apoptosis, angiogenesis and formation of metastases. Due to the different toxicity profile and treatment response of the tumor new predictive factors are searching to select those patients who will most benefit from the treatment with lowest risk of side effects. This review discusses the results of pharmacogenetic studies that describes the influence of polymorphisms on toxicities and tumor response to treatment with application of tyrosine kinase inhibitors. In the future, some of these polymorphisms can become predictive markers applicable in clinical practice. Copyright © 2012 Cornetis. Source

Idasiak A.,II Klinika Radioterapii | Galwas-Kliber K.,II Klinika Radioterapii | Grzadziel A.,Zaklad Planowania Radioterapii i Brachyterapii | Stapor-Fudzinska M.,Zaklad Planowania Radioterapii i Brachyterapii | And 2 more authors.

Stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer in early stages inoperable due to comorbidities, for solitary lung metastases or in case of recurrences of lung cancer after fractionated radiotherapy has gained increased attention over the last years. The present report describes our attempts to implement SBRT with real-time tumor tracking (CyberKnife system) in Gliwice. We also present a brief review of recent literature on this subject. Real-time tumor tracking accounts for tumor motion during respiration by constantly repositioning the radiation beam towards the moving target. This improves the isodose coverage of the tumor and contributes towards normal tissue sparing. A review of the published studies suggests that the control rates in early-stage primary lung cancer treated with SBRT range from 85% to 100%, with acceptable normal tissue reactions. Source

Discover hidden collaborations